Market overview
The global wearable injector market is worth USD 1.1 bn in 2026 and is forecast to reach USD 3.9 bn by 2036, growing at a 13.0% CAGR. United States is the largest country market and Pre-filled on-body injectors is the largest by product segment.
| Scope | On-body wearable injectors that adhere to the skin and deliver large-volume biologic and other drug doses over minutes to hours, including pre-filled and cartridge-based devices. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 1.0 bn |
| Value 2026 | USD 1.1 bn |
| Value 2036 | USD 3.9 bn |
| CAGR 2026-2036 | 13.0% |
| Volume 2026 | 9.21 million units |
| Volume 2036 | 34.6 million units |
| Average price 2026 | USD 124 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Wearable Injector market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 1.1 bn |
| 2027 | USD 1.3 bn |
| 2028 | USD 1.5 bn |
| 2029 | USD 1.6 bn |
| 2030 | USD 1.9 bn |
| 2031 | USD 2.1 bn |
| 2032 | USD 2.4 bn |
| 2033 | USD 2.7 bn |
| 2034 | USD 3.0 bn |
| 2035 | USD 3.4 bn |
| 2036 | USD 3.9 bn |
Wearable Injector market segmentation
By product
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Pre-filled on-body injectors | 46.0% | 53.4% | USD 524 mn | 14.7% |
| Cartridge-based wearable injectors | 34.0% | 30.3% | USD 388 mn | 11.7% |
| Patch pumps for drug delivery | 20.0% | 16.3% | USD 228 mn | 10.7% |
By therapy area
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oncology | 34.0% | 25.9% | USD 388 mn | 9.9% |
| Autoimmune | 26.0% | 30.8% | USD 296 mn | 14.9% |
| Cardiovascular | 18.0% | 23.3% | USD 205 mn | 15.9% |
| Diabetes and metabolic | 12.0% | 10.9% | USD 137 mn | 11.9% |
| Others | 10.0% | 9.1% | USD 114 mn | 11.9% |
By dose volume
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Up to 5 ml | 38.0% | 34.2% | USD 433 mn | 11.8% |
| 5 to 10 ml | 36.0% | 35.4% | USD 410 mn | 12.8% |
| Above 10 ml | 26.0% | 30.5% | USD 296 mn | 14.8% |
By drug
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Biologics | 64.0% | 68.0% | USD 730 mn | 13.7% |
| Small molecule | 20.0% | 16.0% | USD 228 mn | 10.5% |
| Biosimilars | 16.0% | 16.0% | USD 182 mn | 13.0% |
By channel
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Hospital | 30.0% | 28.0% | USD 342 mn | 12.2% |
| Home | 58.0% | 62.0% | USD 661 mn | 13.8% |
| Clinic | 12.0% | 10.0% | USD 137 mn | 11.0% |
Top 25 countries for wearable injector by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 97.0% of 2026 revenue and the 25 countries below together hold 98.9%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 616 mn | 54.0% | USD 2.0 bn | 12.4% |
| 2 | Germany | USD 91 mn | 8.0% | USD 306 mn | 12.9% |
| 3 | United Kingdom | USD 68 mn | 6.0% | USD 240 mn | 13.4% |
| 4 | Japan | USD 68 mn | 6.0% | USD 209 mn | 11.8% |
| 5 | France | USD 57 mn | 5.0% | USD 190 mn | 12.8% |
| 6 | Italy | USD 46 mn | 4.0% | USD 155 mn | 13.0% |
| 7 | China | USD 46 mn | 4.0% | USD 279 mn | 19.8% |
| 8 | Canada | USD 46 mn | 4.0% | USD 159 mn | 13.3% |
| 9 | Spain | USD 34 mn | 3.0% | USD 116 mn | 13.0% |
| 10 | Australia | USD 34 mn | 3.0% | USD 120 mn | 13.4% |
| 11 | Netherlands | USD 4.9 mn | 0.4% | USD 15 mn | 12.2% |
| 12 | Switzerland | USD 3.0 mn | 0.3% | USD 9.3 mn | 12.1% |
| 13 | India | USD 2.2 mn | 0.2% | USD 9.7 mn | 16.1% |
| 14 | Belgium | USD 1.7 mn | 0.1% | USD 5.4 mn | 12.2% |
| 15 | Sweden | USD 1.5 mn | 0.1% | USD 4.6 mn | 12.1% |
| 16 | Austria | USD 1.2 mn | 0.1% | USD 3.9 mn | 11.9% |
| 17 | South Korea | USD 1.1 mn | 0.1% | USD 3.5 mn | 11.8% |
| 18 | Denmark | USD 1.0 mn | 0.09% | USD 3.1 mn | 11.7% |
| 19 | Brazil | USD 0.91 mn | 0.08% | USD 4.3 mn | 16.7% |
| 20 | Mexico | USD 0.91 mn | 0.08% | USD 3.9 mn | 15.6% |
| 21 | Turkey | USD 0.80 mn | 0.07% | USD 3.5 mn | 15.9% |
| 22 | Poland | USD 0.80 mn | 0.07% | USD 3.5 mn | 15.9% |
| 23 | Taiwan | USD 0.68 mn | 0.06% | USD 2.3 mn | 13.0% |
| 24 | Singapore | USD 0.68 mn | 0.06% | USD 3.1 mn | 16.3% |
| 25 | Israel | USD 0.68 mn | 0.06% | USD 2.7 mn | 14.8% |
| Rest of world | USD 12 mn | 1.1% | USD 42 mn | 13.2% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- West Pharmaceutical Services
- Becton Dickinson
- Ypsomed
- Amgen
Group 2: Regional and specialist players
- SHL Medical
- Enable Injections
- Stevanato Group
- Phillips-Medisize
- Gerresheimer
- Owen Mumford
- Eitan Medical
Group 3: Emerging and niche players
- Sensile Medical
- CeQur
- Subcuject
- Sorrel Medical
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the wearable injector market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 13.0% is calculated from the resulting values.
The market is divided by product, by therapy area, by dose volume, by drug, by channel. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the wearable injector market?
The global wearable injector market is estimated at USD 1.0 bn in 2025 and USD 1.1 bn in 2026.
How fast will the wearable injector market grow?
It is forecast to reach USD 3.9 bn by 2036, a compound annual growth rate of 13.0% from 2026, an increase of USD 2.7 bn.
Which country is the largest market for wearable injector?
United States is the largest market by revenue at USD 616 mn in 2026, 54.0% of the global total. The three largest countries together hold 68.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 19.8% a year from 2026 to 2036.
Which wearable injector segment is largest?
In the by product split, Pre-filled on-body injectors is the largest segment with 46.0% of 2026 revenue.
Who are the leading wearable injector companies?
Global leaders include West Pharmaceutical Services, Becton Dickinson, Ypsomed, Amgen.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Catheter-Based Pulmonary Embolism ThrombectomyUSD 1.1 bn · 12.0% CAGR
- Microwave Ablation DevicesUSD 1.2 bn · 9.5% CAGR
- Tablet PressUSD 1.2 bn · 5.5% CAGR
- AI-Accelerated Nonclinical Drug TestingUSD 1.2 bn · 14.0% CAGR
- Multi-Organ Transplant MonitoringUSD 1.1 bn · 9.0% CAGR
- Manufacturing on Demand for MedicalUSD 1.2 bn · 10.0% CAGR
- Urology Ablation DevicesUSD 1.1 bn · 10.0% CAGR
- Advanced Implantable Electrode NeurotechnologyUSD 1.2 bn · 7.8% CAGR